210 related articles for article (PubMed ID: 32949691)
1. Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac.
Winkel D; Werensteijn-Honingh AM; Eppinga WSC; Intven MPW; Hes J; Snoeren LMW; Visser SA; Bol GH; Raaymakers BW; Jürgenliemk-Schulz IM; Kroon PS
Radiother Oncol; 2021 Jan; 154():243-248. PubMed ID: 32949691
[TBL] [Abstract][Full Text] [Related]
2. Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment.
Winkel D; Bol GH; Werensteijn-Honingh AM; Intven MPW; Eppinga WSC; Hes J; Snoeren LMW; Sikkes GG; Gadellaa-van Hooijdonk CGM; Raaymakers BW; Jürgenliemk-Schulz IM; Kroon PS
Radiother Oncol; 2020 May; 146():118-125. PubMed ID: 32146257
[TBL] [Abstract][Full Text] [Related]
3. Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac.
Winkel D; Kroon PS; Werensteijn-Honingh AM; Bol GH; Raaymakers BW; Jürgenliemk-Schulz IM
Acta Oncol; 2018 Dec; 57(12):1705-1712. PubMed ID: 30280631
[TBL] [Abstract][Full Text] [Related]
4. Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases.
Werensteijn-Honingh AM; Jürgenliemk-Schulz IM; Gadellaa-Van Hooijdonk CG; Sikkes GG; Vissers NGPM; Winkel D; Eppinga WSC; Intven M; Raaymakers BW; Kroon PS
Radiother Oncol; 2021 Jan; 154():110-117. PubMed ID: 32950531
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance.
Winkel D; Bol GH; Werensteijn-Honingh AM; Kiekebosch IH; van Asselen B; Intven MPW; Eppinga WSC; Raaymakers BW; Jürgenliemk-Schulz IM; Kroon PS
Phys Imaging Radiat Oncol; 2019 Jan; 9():58-64. PubMed ID: 33458426
[TBL] [Abstract][Full Text] [Related]
6. Individual lymph nodes: "See it and Zap it".
Winkel D; Werensteijn-Honingh AM; Kroon PS; Eppinga WSC; Bol GH; Intven MPW; de Boer HCJ; Snoeren LMW; Hes J; Raaymakers BW; Jürgenliemk-Schulz IM
Clin Transl Radiat Oncol; 2019 Sep; 18():46-53. PubMed ID: 31341975
[TBL] [Abstract][Full Text] [Related]
7. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
[TBL] [Abstract][Full Text] [Related]
8. Investigating the impact of patient arm position in an MR-linac on liver SBRT treatment plans.
van den Wollenberg W; de Ruiter P; Nowee ME; Jansen EPM; Sonke JJ; Fast MF
Med Phys; 2019 Nov; 46(11):5144-5151. PubMed ID: 31529694
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer.
Mohajer J; Dunlop A; Mitchell A; Goodwin E; Nill S; Oelfke U; Tree A
Clin Transl Radiat Oncol; 2021 Jan; 26():1-7. PubMed ID: 33241129
[TBL] [Abstract][Full Text] [Related]
10. Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases.
Cuccia F; Rigo M; Gurrera D; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Attinà G; Pastorello E; De Simone A; Naccarato S; Sicignano G; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3269-3277. PubMed ID: 34268583
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases.
Werensteijn-Honingh AM; Kroon PS; Winkel D; Aalbers EM; van Asselen B; Bol GH; Brown KJ; Eppinga WSC; van Es CA; Glitzner M; de Groot-van Breugel EN; Hackett SL; Intven M; Kok JGM; Kontaxis C; Kotte AN; Lagendijk JJW; Philippens MEP; Tijssen RHN; Wolthaus JWH; Woodings SJ; Raaymakers BW; Jürgenliemk-Schulz IM
Radiother Oncol; 2019 May; 134():50-54. PubMed ID: 31005224
[TBL] [Abstract][Full Text] [Related]
12. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
13. On the feasibility of cardiac substructure sparing in magnetic resonance imaging guided stereotactic lung radiotherapy.
van der Pol LHG; Hackett SL; Hoesein FAAM; Snoeren LMW; Pomp J; Raaymakers BW; Verhoeff JJC; Fast MF
Med Phys; 2023 Jan; 50(1):397-409. PubMed ID: 36210631
[TBL] [Abstract][Full Text] [Related]
14. Adaptive radiotherapy: The Elekta Unity MR-linac concept.
Winkel D; Bol GH; Kroon PS; van Asselen B; Hackett SS; Werensteijn-Honingh AM; Intven MPW; Eppinga WSC; Tijssen RHN; Kerkmeijer LGW; de Boer HCJ; Mook S; Meijer GJ; Hes J; Willemsen-Bosman M; de Groot-van Breugel EN; Jürgenliemk-Schulz IM; Raaymakers BW
Clin Transl Radiat Oncol; 2019 Sep; 18():54-59. PubMed ID: 31341976
[TBL] [Abstract][Full Text] [Related]
15. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
16. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers.
Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N
Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388
[TBL] [Abstract][Full Text] [Related]
17. Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases.
Werensteijn-Honingh AM; Kroon PS; Winkel D; van Gaal JC; Hes J; Snoeren LMW; Timmer JK; Mout CCP; Bol GH; Kotte AN; Eppinga WSC; Intven M; Raaymakers BW; Jürgenliemk-Schulz IM
Phys Imaging Radiat Oncol; 2022 Jul; 23():66-73. PubMed ID: 35814260
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
19. Impact of field number and beam angle on ERE for lung stereotactic body radiotherapy with 1.5T MR-Linac.
Ding S; Liu H; Wang B; Li Y; Li R; Liu B; Xia Y; Huang X
Cancer Radiother; 2021 Jun; 25(4):366-372. PubMed ID: 33622638
[TBL] [Abstract][Full Text] [Related]
20. Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.
McDonald BA; Vedam S; Yang J; Wang J; Castillo P; Lee B; Sobremonte A; Ahmed S; Ding Y; Mohamed ASR; Balter P; Hughes N; Thorwarth D; Nachbar M; Philippens MEP; Terhaard CHJ; Zips D; Böke S; Awan MJ; Christodouleas J; Fuller CD;
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1606-1618. PubMed ID: 33340604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
